ClinicalTrials.gg
CompletedNCT07116694Updated Oct 5, 2026

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

A Phase 2 interventional study of BXCL501 Sublingual Film in Bipolar I Disorder, Bipolar II Disorder and Schizophrenia, sponsored by BioXcel Therapeutics Inc. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by BioXcel Therapeutics Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Enrollment
470th of 704
33 · median 58
Started
2025
with 24 others
Phase 2
92 of 837
9 open now
Registered
810th of 837
by date

Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 470th largest by enrollment of the 704 interventional ones that give a count, is one of 25 that started in 2025, is one of 92 in phase 2, and was the 810th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 837 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.

Read the detailed description

This is an open-label study to assess acute psychomotor agitation measures in patient-informant dyads with adult (18-75 years old) males and females experiencing an agitation episode associated with bipolar I disorder, bipolar II disorder, schizophrenia, schizoaffective disorder, or schizophreniform disorder. This validation study will include collecting data from approximately 30 patient-informant dyads during and following an acute psychomotor agitation episode. Data will be collected during the episodes from the dyads and the clinical rater for up to two hours after baseline. The aim of the informant, patient, and investigator ratings will be to assess rater agreement between investigators and informants, as well as investigators and patients.

03

Conditions studied

  • Bipolar I Disorder
  • Bipolar II Disorder
  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorders
  • Psychomotor Agitation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Participant:

  1. Male and female patients 18 to 75 years old, inclusive.
  2. Patients who can read, understand, and provide written .
  3. Patients who meet the , v5, Text Revision (DSM-5-TR) criteria for a primary diagnosis of bipolar I or bipolar II disorder, schizophrenia, schizoaffective or schizophreniform disorder.
  4. Patients who, in the opinion of the principal investigator, are in good general health prior to study participation as determined by a detailed medical history, a physical examination, and a 12-lead (ECG).
  5. Female participants, if of and sexually active, and male participants, if sexually active with a partner of child-bearing potential, agree to use a medically acceptable and effective method throughout the study and for one month following the end of the study.
  6. Based on history, in the past 30 days prior to Screening, patients must have had at least one clinical presentation of agitation requiring intervention.
  7. Patients who are receiving stable psychotropic treatment for 30 days prior to Screening for the underlying primary diagnosis and who are expected to remain on stable treatment for the duration of the study.

Inclusion Criteria for Informant:

  1. At least 18 years of age at the time of screening.
  2. Is a spouse, significant other, family member, friend, home health aide, or residence manager of an adult patient who:

    1. Has a clinical diagnosis of bipolar I or bipolar II disorder, schizophrenia, schizoaffective or schizophreniform disorder.
    2. Is determined to be eligible for the study per the patient inclusion/exclusion criteria.
  3. Has known the patient for at least 12 months cumulatively.
  4. Currently living with or routinely contacting the patient at least five days a week.
  5. Does not plan to discontinue contact with the patient during the study period.
  6. Willing and able to provide written informed consent.

Exclusion Criteria for Participant:

  1. Patients with serious or unstable medical illnesses. These include current hepatic (moderate-severe hepatic impairment), renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease, congestive heart failure), endocrinologic, or hematologic disease.
  2. Psychiatric comorbidities are generally allowed; however, moderate or severe substance use disorders (SUD) (within the past 6 months) are exclusionary if the substance involved is other than nicotine or caffeine.
  3. The investigator believes the patient has a history of agitation episodes due to substance use.
  4. A diagnosis of antisocial personality disorder, borderline personality disorder, or narcissistic personality disorder that predated the diagnosis of schizophrenia or bipolar disorder, or in the opinion of the Investigator, is independent of the signs and symptoms of the schizophrenia or bipolar disorder.
  5. Suicidality as assessed with the Columbia Suicide Severity Rating Scale (C-SSRS). risk of suicide based on the Investigator's clinical opinion or a history of an actual suicide attempt in the last year are also exclusionary.
  6. Female patients who have a positive pregnancy test at screening/baseline or are breastfeeding.
  7. Currently treated with alpha-1 noradrenergic blockers (terazosin, doxazosin, tamsulosin, alfuzosin, or prazosin), alpha-2 adrenergic agonists, or other prohibited medications.
  8. Patients with hydrocephalus, seizure disorder, or history of significant head trauma, stroke, , subarachnoid bleeding, brain tumor, encephalopathy, meningitis, Parkinson's disease, or focal neurological findings.
  9. Patients with ECG abnormalities considered clinically significant by the Investigator or qualified designee with clinical implications for the patient's participation in the study.
  10. Patients who have received an drug within 30 days prior to Baseline.
  11. For any reason, patients considered by the Investigator, or designee, to be unsuitable candidates for receiving dexmedetomidine, e.g., patients with a history of allergic reactions to dexmedetomidine.

Exclusion Criteria for Informant:

  1. Appears to have an impairment (e.g., cognitive, hearing, visual) or insufficient knowledge of the English language that could interfere with their ability to provide written consent, complete written assessments, or an interview (based on screener judgment).
  2. Unable to accompany the patient and remain present at the clinical site to complete ratings for the full two-hour data collection period while the patient experiences an acute agitation episode that needs to be treated.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    BXCL501 Sublingual film

    Experimental: 120 mcg of BXCL501 Sublingual film containing 120 Micrograms Dexmedetomidine

    Drug: BXCL501 Sublingual Film

Interventions

06

What researchers measure

Primary outcomes

  1. Informant and Clinician ratings comparison

    The aim of the study is to assess the agreement/correlations among different measures so the comment is correct that different units of measure are being assessed. The informant-completed questionnaire (modified clinical global impression of severity for informants (mCGI-S-INF) and the clinical-rater completed questionnaire, Positive and Negative Syndrome Scale - Excited Component (PEC) are the primary outcomes being assessed. The mCGI-S-INF is a single item with a 0 to 3 point scale with higher values indicating more severe agitation. The PEC is a five item questionnaire with 7-point response options, overall scores range from 5 to 35 with higher scores indicating more severe agitation.

    Time frame: Before and 2 hours after the intervention

  2. Informant training materials assessment

    Assess content validity of the Modified Clinical Global Impression of Severity for Informants (mCGI-S-INF) and informant training materials. The scale being utilized is mCGI-S-INF. There is no score as it is a qualitative assessment and it is being validated to measure patient informant reported outcomes against patient reported outcomes (mCGI-S-PAT) and physician reported outcomes using the Positive and Negative Syndrome Scale - Excited Component (PEC) scale where the highest score indicates the maximum agitation that could be experienced.

    Time frame: Within 7 days of the intervention

Secondary outcomes

  1. Patient and Clinician ratings comparison

    The aim of the study is to assess the agreement/correlations among different measures so the comment is correct that different units of measure are being assessed. The patient-completed questionnaire (modified clinical global impression of severity for patients (mCGI-S-P) and the clinical-rater completed questionnaire, Positive and Negative Syndrome Scale - Excited Component (PEC) are the primary outcomes being assessed. The mCGI-S-P is a single item with a 0 to 3 point scale with higher values indicating more severe agitation. The PEC is a five item questionnaire with 7-point response options, overall scores range from 5 to 35 with higher scores indicating more severe agitation.

    Time frame: Before and 2 hours after the intervention

  2. Patient training materials assessment

    Assess content validity of the Modified Clinical Global Impression of Severity for Patients (mCGI-S-PAT) training materials. The scale being utilized is mCGI-S-PAT. There is no score as it is a qualitative assessment and is being validated to measure patient reported outcomes against physician reported outcomes using the Positive and Negative Syndrome Scale - Excited Component (PEC) scale where the highest score indicates the maximum agitation that could be experienced.

    Time frame: Within 7 days of the intervention

  3. Patients completion of the Modified Clinical Global Impression of Severity for Patients (mCGI-S-PAT)

    Evaluate whether patients with acute psychomotor agitation can complete the Modified Clinical Global Impression of Severity for Patients (mCGI-S-PAT) evaluation tool. The mCGI-S-PAT is already in the trial protocol and this protocol so it would be disruptive to rename the item at this point. The measure assesses severity of agitation 'right now' with response options of none, mild, moderate, and severe.

    Time frame: Before and 2 hours after the intervention

07

Study locations

5 sites
  • BioXcel Clinical Research Site 103
    Chino, California 91710, United States
  • BioXcel Clinical Research Site 105
    Oceanside, California 92056, United States
  • BioXcel Clinical Research Site 102
    Orange, California 92868, United States
  • BioXcel Clinical Research Site 101
    St Louis, Missouri 63125, United States
  • BioXcel Clinical Research Site 106
    Las Vegas, Nevada 89119, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Oct 2025, 3 months.

Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Aug 11, 2025
StartActual
Jun 19, 2025
Primary completionActual
Oct 7, 2025
CompletionActual
Oct 7, 2025
Results delay requested
Oct 1, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and registry dates
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07116694
Lead sponsor
BioXcel Therapeutics Inc
Collaborators
Premier Research
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Jun 19, 2025
Primary completion
Oct 7, 2025
Completion
Oct 7, 2025
Last update
Oct 5, 2026

Study contacts

BioXcel MM
study chair · BioXcel Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion